Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inbox Gmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscription Click this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Today's Bonus News The Often-Missed Corner of Healthcare That Wall Street Is LovingReported by Nathan Reiff. Published: 3/29/2026. 
Key Points - Numerous lab equipment stocks are down in the high-teens so far this year, but seemingly modest sales growth may hide fundamental strengths.
- These companies can present a more secure approach to the healthcare industry than some higher-risk alternatives.
- Still, headwinds including tariff impacts and inflation remain a concern.
- Special Report: Elon Musk: This Could Turn $100 into $100,000
The healthcare industry is notoriously volatile—company fortunes can be made or broken on the success of a single product or the results of a clinical trial—and it's not uncommon for stocks in this sector to see some of the wildest spikes and drops across the market. Investors who want exposure to the healthcare space but are wary of that turbulence might adopt a "picks-and-shovels" approach, focusing on companies that provide essential equipment and services to the industry rather than higher-risk names in areas like pharmaceuticals. Lab equipment stocks are often overlooked by investors in healthcare, even though several companies in this subindustry are among the largest in the sector. With several external forces that could affect healthcare in 2026—shifting subsidies, an aging population with greater needs, inflation, the growing role of AI, and more—core lab equipment names may look more attractive than usual. Below are some of the major players worth a closer look. A Recent Dip Masks Thermo Fisher's Long-Term Strengths BlackRock, JPMorgan, Goldman Sachs, and Fidelity are accumulating shares of one scarce resource - the fuel powering a new $382 trillion digital financial infrastructure. With $909 billion migrating onto these new digital rails every single day, demand is projected to climb 12,000% by April 2027. The Nasdaq has SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this shift. Veteran tech investor Andy Howard has identified the single asset positioned to power the entire grid - and the free ticker is available now. See the scarce asset behind the $382 trillion money grid today $182 billion life sciences solutions, diagnostics, and analytical instruments company Thermo Fisher Scientific (NYSE: TMO) has had a difficult start to 2026, with shares down more than 15% year-to-date (YTD). The company recently fell into TradeSmith's red zone for financial health. Much of the recent weakness appears tied to tariffs and foreign-exchange volatility, which together depressed margins by over 100 basis points in 2025. There are, however, several bright spots in Thermo Fisher's recent performance. In Q4 2025, revenue of $12.2 billion rose 7% year-over-year (YOY), beating analyst expectations by about $250 million. Adjusted earnings per share (EPS) also topped forecasts at $6.57. That momentum may reflect recent product launches, including the Orbitrap Astral Zoom mass spectrometer and new bioreactor offerings. Thermo Fisher's broad business model and diverse product mix should provide a buffer against external pressures. Even if 2026 guidance is conservative (revenue expected to climb 4%–6%), anticipated improvements to EBITDA margins and steady customer demand are positive signs. That may explain why analysts remain largely favorable: 17 of 19 rate the stock a Buy or equivalent, and consensus estimates imply more than 29% upside. Danaher's Business May Be Improving, Even as Guidance Remains Modest Danaher Corp. (NYSE: DHR) shares are down nearly 20% YTD, placing the instruments, consumables, and reagents firm in a position similar to Thermo Fisher. While 2026 guidance suggests modest core revenue growth of 3% to 6% YOY, the latest quarter included a top- and bottom-line beat and the company generated $5.3 billion in free cash flow for 2025. Notable growth drivers for 2026 include Danaher's bioprocessing business, which is expected to deliver high-single-digit revenue growth driven by strong monoclonal antibody demand, and its diagnostics segment, which could benefit from new FDA clearances. Equipment orders have begun improving after a prolonged weak period, which could further support sales growth. Analysts are relatively optimistic about DHR, forecasting roughly 12.3% earnings growth over the next year and about 35% potential share-price appreciation. That outlook is reflected in ratings: 19 of 22 analysts rate the stock a Buy. Agilent's Biocare Purchase Could Be a Catalyst Agilent Technologies (NYSE: A) appears to lag the companies above based on its latest earnings, which showed only 4.4% YOY revenue growth and marginal misses on both revenue and earnings versus expectations. Still, Agilent may have a hidden growth engine in its recent acquisition of Biocare Medical, which should strengthen its position in cancer diagnostics. Although the Biocare deal cost nearly $1 billion, it could add recurring revenue in a growing, higher-margin area—potentially helping Agilent's operating margin, which was 24.6% in the last quarter. Despite a YTD decline of about 17%, analysts see substantial upside for Agilent, with consensus estimates implying roughly 42% potential appreciation. Wall Street's view is generally positive: the stock is rated a Moderate Buy, with 13 of 16 analysts assigning Buy-equivalent ratings. | 